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OBJECTIVEdWe examined the prevalence, extent, severity, and prognosis of coronary artery
disease (CAD) in individuals with andwithout diabetes (DM) who are similar in CAD risk factors.
RESEARCH DESIGN ANDMETHODSdWe identiﬁed 23,643 consecutive individuals
without known CAD undergoing coronary computed tomography angiography. A total of 3,370
DM individuals were propensity matched in a 1-to-2 fashion to 6,740 unique non-DM individ-
uals. CAD was deﬁned as none, nonobstructive (1–49% stenosis), or obstructive ($50% steno-
sis). All-cause mortality was assessed by risk-adjusted Cox proportional hazards models.
RESULTSdAt a 2.2-year follow-up, 108 (3.2%) and 115 (1.7%) deaths occurred among DM
and non-DM individuals, respectively. Compared with non-DM individuals, DM individuals
possessed higher rates of obstructive CAD (37 vs. 27%) and lower rates of having normal arteries
(28 vs. 36%) (P , 0.0001). CAD extent was higher for DM versus non-DM individuals for
obstructive one-vessel disease (19 vs. 14%), two-vessel disease (9 vs. 7%), and three-vessel
disease (9 vs. 5%) (P , 0.0001 for comparison), with higher per-segment stenosis in the prox-
imal and mid-segments of every coronary artery (P , 0.001 for all). Compared with non-DM
individuals with no CAD, risk of mortality for DM individuals was higher for those with no CAD
(hazard ratio 3.63 [95% CI 1.67–7.91]; P = 0.001), nonobstructive CAD (5.25 [2.56–10.8]; P,
0.001), one-vessel disease (6.39 [2.98–13.7]; P , 0.0001), two-vessel disease (12.33 [5.622–
27.1]; P , 0.0001), and three-vessel disease (13.25 [6.15–28.6]; P , 0.0001).
CONCLUSIONSdCompared with matched non-DM individuals, DM individuals possess
higher prevalence, extent, and severity of CAD. At comparable levels of CAD, DM individuals
experience higher risk of mortality compared with non-DM individuals.
Diabetes Care 35:1787–1794, 2012
Current AmericanDiabetes Associationguidelines endorse the widespreaduse of cardiovascular prevention
measures for individuals with diabetes
(DM) based upon an abundance of ob-
servational and population-based studies
demonstrating excess cardiovascular risk
and death attributable to diabetes (1).
However, previous observational data ex-
amining the precise incremental risk of
DM for future adverse coronary artery dis-
ease (CAD) events have demonstrated
variability, and outcomes-based analyses
of DM individuals generally have lacked
information regarding CAD prevalence,
extent, and severity (2–5).
Coronary computed tomography an-
giography (CCTA) is a noninvasive imag-
ing test that demonstrates high diagnostic
performance for the detection and ex-
clusion of CAD, with recent multicenter
studies demonstrating a robust prognos-
tic utility to CCTA CAD ﬁndings for the
prediction of mortality and other major
adverse cardiac events (6–9). CCTA stud-
ies to date have examined CAD ﬁndings
and prognosis in DM individuals but
have been limited to single centers in
small patient cohorts (n = 140–313)
(10,11). In addition, DM and non-DM
individuals within these studies demon-
strated important differences in age, sex,
and CAD risk factors, thus precluding the
precise inﬂuence of the DM state to CAD
presence and risk.
From a large international prospec-
tive multicenter observational cohort
study of individuals undergoing CCTA,
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
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we thus sought to compare the preva-
lence, extent, severity, and prognosis of
CAD for propensity-matched DM and
non-DM individuals.
RESEARCH DESIGN AND
METHODSdThe COronary CT Angi-
ography EvaluatioN For Clinical Out-
comes: An InteRnational Multicenter
Registry (CONFIRM) is a dynamic, pro-
spective, international multicenter regis-
try whose rationale and design has been
described previously (12). In brief, the
CONFIRM enrolled consecutive adults,
aged $18 years, between 2005 and
2009 who underwent $64-detector row
CCTA for suspected CAD at 12 centers
(Cedars Sinai Medical Center, Los An-
geles, CA; Harbor University of California
Los Angeles Medical Center, Los Angeles,
CA; Tennessee Heart and Vascular Insti-
tute, Hendersonville, TN; Capital Cardi-
ology Associates, Albany, NY; University
ofMunich,Munich,Germany;OttawaHeart
Institute, Ottawa, Ontario, Canada; Henry
Ford Medical Center, Detroit, Michigan;
Yonsei Medical Center, Seoul, Korea; Uni-
versity Hospital, Zurich, Switzerland;
William Beaumont Hospital, Royal Oak,
MI ; Walter Reed Armey Medical Center,
Washington, DC; University Hospital of
Parma, Parma, Italy) from six countries.
Individuals with known CAD, as deﬁned
by prior myocardial infarction or coronary
revascularization, were excluded from the
current study analysis.
All patients were in normal sinus
rhythm and were capable of the breath
hold needed for CCTA. Patients with
heart rates.70 beats per minute (bpm)
were given oral or intravenous meto-
prolol as per local site protocol. All cen-
ters used intravenous metoprolol at the
time of CCTA performance to lower
heart rates to ,70 bpm. If the patient’s
heart rate did not drop to ,70 bpm,
CCTA was performed at the lowest
heart rate.
Prior to the initiation of the scan, we
prospectively collected information on
the presence of categorical cardiac risk
factors in each individual. Systemic arte-
rial hypertension was deﬁned as a docu-
mented history of high blood pressure or
treatment with antihypertensive medi-
cations. DM was deﬁned by a previous
diagnosis of DM made by a physician
(using a fasting glucose threshold of
$126 mg/dL) and/or use of insulin or
oral hypoglycemic agents. Dyslipidemia
was deﬁned as known but untreated
dyslipidemia or current treatment with
lipid-lowering medications. A positive
smoking history was deﬁned as current
smoking or cessation of smoking within
3 months of testing. Family history of
premature coronary heart disease was de-
termined by patient query. Symptom pre-
sentation was classiﬁed into one of four
categories: typical angina, atypical angina,
noncardiac pain, or dyspnea. Age, sex,
and angina typicality for each patient
were used to determine the expected
pretest probability of CAD with .50%
luminal diameter stenosis according to
Diamond and Forrester criteria (13).
Scan protocol and image
reconstruction
CCTA scans were performed on multiple
scanner platforms (Light speed VCT, GE
Healthcare, Milwaukee, WI; Somatom
Deﬁnition CT, Siemens, Ehrlangen,
Germany; Somatom Deﬁnition Flash CT,
Siemens, Ehrlangen, Germany). During
the CCTA acquisition, 80–140 mL iodin-
ated contrast (Isovue 370, Bracco Diag-
nostics, Princeton, NJ; Omnipaque, GE
Healthcare, Princeton, NJ; Visipaque,
GE Healthcare, Princeton, NJ; Imeron
350, Bracco Atlana Pharma, Konstanz,
Germany) was injected. Contrast timing
was performed to optimize uniform con-
trast enhancement of the coronary arter-
ies. The scan parameters were 64 3
0.625/0.750 mm collimation and tube
voltage 100 or 120 kVp, and the tube
current was assigned based on body size
and scanner platform.
Dose-reduction strategies, including
electrocardiogram-gated tube current
modulation, reduced tube voltage, and
prospective axial triggering, were used
whenever feasible. Estimated radiation
doses ranged from 3 to 18 mSv.
Helical or axial scan data were ob-
tained with retrospective or prospective
electrocardiogram gating, respectively.
Images were reconstructed immediately
after completion of the scan to identify
motion-free coronary artery images. Op-
timal phase reconstruction was assessed
by comparison of different phases, if avail-
able, and the phase with the least amount
of coronary artery motion was chosen
for analysis. Multiple phases were used
for image interpretation if minimal coro-
nary artery motion was different for dif-
ferent arteries. CCTAs were evaluated by
an array of postprocessing imaging tech-
niques, including axial, multiplanar refor-
mat, maximum intensity projection,
and short-axis cross-sectional views. In
all individuals, irrespective of image qual-
ity, every arterial segment was scored in
an intent-to-diagnose fashion. If a coro-
nary artery segment was uninterpretable
despite these multiple techniques, the
nonevaluable segment was scored simi-
larly to the most proximal segment that
was evaluable.
Noninvasive coronary artery
analysis by CCTA
All scanswere analyzedby level III–certiﬁed
cardiologists with experience interpret-
ing several thousand CCTA scans.
In direct accordance with the Society
of Cardiovascular Computed Tomogra-
phy guidelines, CCTA interpretation was
uniform across all study sites, with coro-
nary segments visually scored for the
presence of coronary plaque using a
16-segment coronary artery model in an
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
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intent-to-diagnose fashion (14). In each
coronary artery segment, coronary athero-
sclerosis was deﬁned as tissue structures
.1 mm2 that existed either within the
coronary artery lumen or adjacent to the
coronary artery lumen that could be
discriminated from surrounding pericar-
dial tissue, epicardial fat, or the vessel lu-
men itself. Coronary atherosclerotic
lesions were quantiﬁed for stenosis by vi-
sual estimation. Luminal diameter steno-
sis severity was scored as none (0%
luminal stenosis), nonobstructive (1–
49% luminal stenosis), or obstructive
($50% luminal stenosis). Percent ob-
struction of coronary artery lumen was
based on a comparison of the luminal di-
ameter of the segment exhibiting obstruc-
tion to the luminal diameter of the most
normal-appearing site immediately proxi-
mal to the plaque. In instances in which
plaquewashighly calciﬁed, two-dimensional
oblique images also were visualized with-
out maximal intensity projection (i.e.,
0.625–0.75mm isotropic voxel resolution)
or multiplanar reformats with cross-
sectional views tominimize partial volume
averaging artifact of calcium.
Plaque severity was graded on a per-
patient, per-vessel, and per-segment
level. Per-patient maximal stenosis sever-
ity was deﬁned by the maximum intra-
luminal stenosis in any of the coronary
segments at the$50% stenosis threshold.
For purposes of classiﬁcation for per-
vessel analyses, we considered four
arterial territories: left main artery, left
anterior descending (LAD) artery, left
circumﬂex (LCx) artery, and right coro-
nary artery (RCA). Obstructive CAD in
the diagonal branches, obtuse marginal
branches, and posterolateral branches
was considered to be part of the LAD,
LCx, and RCA system, respectively. The
posterior descending artery was consid-
ered as part of the RCA or LCx system,
dependent upon the coronary artery
dominance. A $50% stenosis in the left
main artery was considered obstructive in
all models. Per-vessel CAD severity was
deﬁned by $50% stenosis in zero, one,
two, or three coronary artery vessels.
Per-segment analysis was judged for
individual coronary artery segments that
included the left main artery; proximal,
mid-, and distal LAD; ﬁrst and second
diagonal branch; proximal and distal
LCx; ﬁrst and second obtuse marginal
branch; proximal, mid-, and distal RCA;
left and right posterolateral artery;
and posterior descending artery. Clinical
coronary artery plaque scores were
calculated, as we have previously described
(15). A segment involvement score (SIS)
reﬂected CAD distribution and was cal-
culated as the total number of coronary
artery segments exhibiting plaque, irre-
spective of the degree of luminal stenosis
within each segment (minimum = 0; max-
imum = 16). A segment stenosis score
(SSS) was used as a measure of overall cor-
onary artery plaque burden. Each individ-
ual coronary segment was graded as
having no to severe plaque (i.e., scores
from 0 to 3) based on the extent of the
obstruction of the coronary luminal diam-
eter. Then, the extent scores of all 16 indi-
vidual segments were summed to yield a
total score ranging from 0 to 48.
Follow-up
The primary end point was time to death
from all causes. Follow-up procedures
were approved by all study centers’ insti-
tutional review boards. Death status for
non-U.S. centers was gathered by clinical
visits, telephone contacts, and question-
naires sent by mail, with veriﬁcation of all
reported events by hospital records or di-
rect contact with a patient’s attending
physician. Death status for U.S. centers
was ascertained either by query of the So-
cial Security Death Index or by direct phy-
sician and/or patient contact.
Statistical analysis
SPSS version 12.0 (SPSS, Chicago, IL)
and SAS version 9.2 (SAS, Cary, NC) were
used for all statistical analyses. Categori-
cal variables are presented as frequencies
and continuous variables as means 6 1
SD. Variables were compared with the
x2 statistic for categorical variables and
by Student unpaired t tests for continuous
variables. Time to death from all causes
and death rates were calculated using uni-
variable Cox proportional hazards mod-
els. In each case, the proportional hazards
assumption was met. Adjusted models
also were devised, including multivari-
able stepwise models adjusting for base-
line demographics, CAD risk factors,
angina typicality, and pretest likelihood
of obstructive CAD. Adjusted models
were also developed to test ﬁrst-order in-
teractions related to age, sex, and study
site. A two-tailed P value,0.05 was con-
sidered statistically signiﬁcant.
To compare the effects of DM status
on CAD prevalence, extent, severity, and
prognosis, we constructed a propensity
score for DM by multivariate logistic re-
gression for age, sex, dyslipidemia, hy-
pertension, smoking, and family history
of premature CAD. A total of 3,370 DM
patients were propensity matched in a
1-to-2 fashion by age, sex, and CAD risk
factors to 6,740 unique non-DM patients
up to eight decimal places. In all matched
patients, the balancing property was
achieved. Propensity-matched groups
then were compared using the Wilcoxon
rank sum tests for continuous variables
and the McNemar test for categorical
variables in univariable analysis, with
Cox proportional hazards regression per-
formed comparing the overall propensity
matched DM and non-DM groups for
presence, extent, severity, and prognosis
related to CAD ﬁndings by CCTA.
RESULTS
Clinical characteristics of the
study group
After propensity matching, the DM group
consisted of 3,370 individuals and the
non-DM group consisted of 6,740 indi-
viduals (Table 1). Propensity-matched
DM and non-DM groups were similar
for age, sex, and CAD risk factors, with
differences in pretest likelihood of ob-
structive CAD and prevalence of asymp-
tomatic individuals.
Among matched DM and non-DM
individuals, CAD prevalence, extent, and
severity differed (Table 1). On a per-
patient basis, as compared with non-DM
individuals, DM individuals exhibited
lower prevalence of normal coronary ar-
teries and higher rates of obstructive
CAD. On a per-vessel basis, higher rates
of obstructive one-vessel, two-vessel, and
three-vessel disease or left main disease
were noted for DM individuals compared
with matched non-DM individuals. Both
SSS and SIS for overall population were
similar (median of 2 [interquartile ranges
0–5 and 0–4], respectively). Overall, SSS
for DM individuals was higher than non-
DM individuals (3 vs. 2, P , 0.0001).
Likewise, overall SIS for DM individuals
was also higher than non-DM individuals
(2 vs. 1, P , 0.0001). On a per-segment
basis, DM individuals possessed higher
segmental stenosis scores compared
with non-DM individuals for nearly every
coronary segment and for all proximal
and mid-coronary segments (Table 2).
Clinical factors and risk of
mortality in matched DM and
non-DM individuals
Survival was examined after a median
follow-up of 2.2 years (interquartile range
1.5–3.1). DM individuals experienced
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a signiﬁcantly higher rate of death
(n = 108 [3.2%]) compared with non-
DM individuals (n = 115 [1.7%]) (P ,
0.0001). Among DM individuals, age
and dyslipidemia were associated with in-
creased risk of mortality (P , 0.0001 for
both), whereas male sex, hypertension,
family history of CAD, current smoking,
and pretest CAD likelihood was not (P.
0.05 for all) (Table 3). Clinical factors as-
sociated with death in non-DM individu-
als also included age (P , 0.001) and
dyslipidemia (P = 0.006), as well as hy-
pertension (P = 0.01). In non-DM indi-
viduals, low pretest likelihood of CAD
was associated with a signiﬁcantly lower
risk of death, a ﬁnding not observed for
DM individuals.
CAD ﬁndings and risk of mortality
in matched DM and non-DM
individuals
On a per-patient basis, when using a non-
DM individual without CAD as a refer-
ence, both DM state and increasing se-
verity of CAD were associated with
increased risk of mortality. In multivari-
able analyses, as compared with a non-DM
individual with no CAD, risk of mortality
increased for non-DM individuals with
nonobstructive CAD (hazard ratio [HR]
3.12 [95%CI 1.55–6.21], P = 0.0013), DM
individuals with no CAD (3.63 [1.67–
7.92], P = 0.001), DM individuals with
nonobstructive CAD (5.25 [2.56–10.8],
P, 0.0001), non-DM individuals with ob-
structive CAD (6.8 [3.52–13.1], P ,
0.0001), and DM individuals with obstruc-
tive CAD (9.39 [4.85–18.2], P , 0.0001).
On a per-vessel basis, multivariable risk-
adjusted analyses similarly demonstrated
an increased risk for DM individuals
for nonobstructive CAD; one-vessel, two-
vessel, and three-vessel disease; or left
main disease (Fig. 1).
CONCLUSIONSdThese present re-
sults of the CONFIRM represent the ﬁrst
prospective multicenter data to relate per-
patient, per-vessel, and per-segment
prevalence, extent, and severity of CAD
ﬁndings by CCTA for DM and non-DM
individuals who are similar to each other
in age, sex, and CAD risk factors. Given
the study size, high number of sites, and
international nature of the CONFIRM,
our ﬁndings enable quantiﬁcation of ex-
cess CAD among DM individuals com-
pared with non-DM individuals with high
precision and can be considered widely
generalizable. Of interest, increased prev-
alence, extent, and severity of CAD for
DM individuals were remarkably consis-
tent across patient-, vessel-, and segment-
based comparisons. Individuals with DM
possessed a 37% higher prevalence of
obstructive CAD at a per-patient level,
which was consistent with the 36 and
29% increase in prevalence of obstructive
one-vessel and two-vessel disease, respec-
tively, at the per-vessel level. Among
segmental analyses for proximal and
mid-portions of coronary arteries, steno-
sis scores ranged between 26 and 40%
higher for DM individuals compared with
matched non-DM individuals.
In addition, to our knowledge, our
ﬁndings represent the ﬁrst multicenter
data to associate CCTA CAD ﬁndings to
incident mortality for matched DM and
non-DM individuals. For individuals with
no, nonobstructive, and obstructive CAD,
increased risk of mortality was evident for
DM compared with non-DM individuals.
As compared with non-DM individuals
without CAD, the risk of mortality was
more than ﬁvefold higher for DM indi-
viduals with nonobstructive CAD and
almost 10-fold higher for DM individuals
with obstructive CAD. When CAD extent
and severity was stratiﬁed on a per-vessel
analysis as no CAD, nonobstructive CAD,
or obstructive one-vessel, obstructive
two-vessel, or obstructive three-vessel
disease, the risk of mortality associated
with the DM state resulted in the “step up”
of a CAD risk category for non-DM indi-
viduals. As an example, the hazard for
mortality for a DM individual with no
CAD by CCTAwas 3.63, whereas the haz-
ard for a non-DM individual with nonob-
structive CAD by CCTA was 3.12.
Likewise, the hazard for death for a DM
individual with nonobstructive CAD was
5.25, which was comparable to the 5.56
noted for non-DM individuals with ob-
structive one-vessel disease (Fig. 1).
Previous studies examining the prog-
nostic value of CT for DM individuals
have been limited to smaller study sizes
and to single centers. Hadamitzky et al.
(10) studied 140 DM individuals com-
pared with 1,782 non-DM individuals
for measures of incident cardiac events,
as deﬁned by all-cause mortality, nonfatal
myocardial infarction, or unstable angina
requiring hospitalization. In this study, a
positive relationship was noted toward an
Table 1dBaseline characteristics and coronary artery ﬁndings of matched DM and
non-DM individuals
Variable DM No DM P
n 3,370 6,740
Baseline characteristics
Age (years) 60.5 (11) 60.7 (11.1) 0.39
Male sex (%) 1,746 (52) 3,559 (53) 0.34
Hyperlipidemia (%) 2,359 (70) 4,685 (70) 0.61
Hypertension (%) 2,365 (70) 4,725 (70) 0.94
Current smoker (%) 605 (18) 1,244 (18) 0.54
Family history of CAD (%) 1,305 (39) 2,585 (38) 0.72
Pretest CAD likelihood 0.01
Low (%) 651 (22) 1,509 (25)
Intermediate (%) 1,907 (66) 3,833 (64)
High (%) 338 (12) 644 (11)
Chest pain symptoms*
Asymptomatic (%) 887 (30) 2,058 (34) 0.0006
Noncardiac/dyspnea (%) 367 (13) 739 (12) 0.6354
Atypical angina (%) 1,147 (39) 2,264 (38) 0.0901
Typical angina (%) 508 (17) 965 (16) 0.0837
Per patient
Normal (%) 947 (28) 2,447 (36) ,0.0001
Nonobstructive (%) 1,179 (35) 2,498 (37) 0.0407
Obstructive (%) 1,244 (37) 1,795 (27) ,0.0001
Per vessel
Normal (%) 947 (28) 2,447 (36) ,0.0001
Nonobstructive (%) 1,179 (35) 2,498 (37) 0.0407
One-vessel (%) 640 (19) 974 (14) ,0.0001
Two-vessel (%) 304 (9) 458 (7) ,0.0001
Three-vessel/left main (%) 300 (9) 363 (5) ,0.0001
Data are mean (SD) unless otherwise indicated. *Chest pain symptoms missing in 518 patients.
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adverse prognosis for DM individuals for
the number of coronary plaques using an
atherosclerotic burden score, which was a
measure of total number of visualized cor-
onary plaques. Higher plaque number
conferred a 1.3 increased hazards (95%
CI 1.1–1.7) for each additional lesion
noted (P = 0.005). van Werkhoven et al.
(11) compared 313 DM individuals to
303 non-DM individuals for CAD preva-
lence, distribution and a composite end
point of cardiac death, nonfatal myocar-
dial infarction, and unstable angina re-
quiring hospitalization; DM individuals
with obstructive CAD by CCTA experi-
enced a 47% event rate, as compared
with a 36% event rate for non-DM indi-
viduals with obstructive CAD. This study
also observed no adverse cardiac events
at the 20-month follow-up for both DM
and non-DM individuals without evident
CAD by CCTA. Our study extends these
previous study ﬁndings by not only ex-
amining differences in CAD prevalence,
extent, and severity but also prognosis
in DM and non-DM individuals matched
for age, sex, and other traditional CAD
risk factors. In addition, we examined these
differences between DM and non-DM in-
dividuals on a per-patient, per-vessel, and
per-segment basis.
In direct contrast to the data reported
by van Werkhoven, our study observed a
higher risk of mortality for DM individuals
without CAD when compared with non-
DM individuals without CAD. These data
are in direct accordance with the recent
report from the Emerging Risk Factors
Collaboration (16), which identiﬁed
hazards for mortality from individual-
participant data for 123,205 deaths
among 820,900 people in 97 prospective
studies. In this study, risk of mortality for
DM individuals was 1.80-fold higher
(95% CI 1.71–1.90) than for non-DM
individuals for all-cause mortality.
Cause-speciﬁc death analysis revealed
that the elevated risk of death was not
only associated with cardiovascular but
also noncardiovascular causes, including
death from cancer (HR 1.25 [95% CI
1.19–1.31]), death from vascular causes
(2.32 [2.11–2.56]), and death from other
causes (1.73 [1.62–1.85]); our data are
consistent with these ﬁndings. In the
current study, among 18 deaths that oc-
curred for DM individuals with no evi-
dent CAD by CCTA, exploration of
medical records revealed the causes of
death to be related to complications
of noncardiovascular diseases, such as
pneumonia, liver disease, or renal fail-
ure. Of interest, although cause-speciﬁc
death could be ascertained only for 12 of
18 DM patients without CCTA evidence
of CAD, no cases of sudden cardiac death
or myocardial infarction–related death
were observed.
CCTA is a novel noninvasive imaging
modality, which extends visualization
of coronary atherosclerosis beyond that
which is capable by coronary artery cal-
cium scoring (CACS). By contrast-
enhancedmethods, CCTA offers the added
diagnostic ability to visualize noncalciﬁed
components of atherosclerotic plaque,
along with coronary artery remodeling
and can provide measurement of plaque
volumes (17,18). Use of CCTA generally
has been endorsed for low-to-intermediate
risk individuals by professional societal
appropriate-use criteria (19), whereas the
use of CACS has been advocated for
asymptomatic individuals (20). In this re-
gard, CACS has been associated with a
heightened rate of mortality with escalat-
ing CACS score in individuals with diabe-
tes (21), but previous direct comparative
studies evaluating the role of CACS versus
CCTA in patients with diabetes is lacking.
Stress myocardial perfusion imaging
(MPI) represents another alternative to
CACS or CCTA for risk stratiﬁcation of
patients with diabetes, but previous stud-
ies have demonstrated a nonnegligible
false-negative rate for diabetic individuals
undergoing MPI (22). Future studies ex-
amining the differential clinical utility of
CCTA, CACS, and MPI in diabetic popu-
lations now seem warranted.
Although this study addresses several
of the shortcomings of previous studies
Table 2dSSS for matched DM and non-DM individuals
Coronary segment
DM No DM P
n
Percent
with CAD
Stenosis
score n %
Stenosis
score
Stenosis
score
Percent
with CAD
Left main artery 640 19 0.23 6 0.52 1,070 16 0.18 6 0.45 ,0.0001 ,0.0001
LAD artery
Proximal 1,794 54 0.78 6 0.88 3,084 46 0.62 6 0.79 ,0.0001 ,0.0001
Mid 1,461 45 0.72 6 0.95 2,486 38 0.57 6 0.84 ,0.0001 ,0.0001
Distal 417 14 0.20 6 0.57 618 10 0.14 6 0.47 ,0.0001 ,0.0001
Diagonal artery 1 554 18 0.28 6 0.69 844 14 0.21 6 0.58 ,0.0001 ,0.0001
Diagonal artery 2 160 8 0.12 6 0.45 254 6 0.09 6 0.38 0.0037 0.003
LCx artery
Proximal 968 30 0.42 6 0.74 1,488 23 0.30 6 0.62 ,0.0001 ,0.0001
Distal 388 13 0.19 6 0.54 604 10 0.15 6 0.51 0.0022 ,0.0001
Obtuse marginal 1 390 13 0.20 6 0.61 596 10 0.15 6 0.50 ,0.0001 ,0.0001
Obtuse marginal 2 88 8 0.11 6 0.43 170 7 0.10 6 0.43 0.6535 0.38
RCA
Proximal 1,088 33 0.48 6 0.79 1,830 28 0.37 6 0.69 ,0.0001 ,0.0001
Mid 883 28 0.43 6 0.80 1,393 22 0.32 6 0.70 ,0.0001 ,0.0001
Distal 433 15 0.21 6 0.58 740 13 0.17 6 0.52 0.0016 0.003
Left PL artery 56 4 0.06 6 0.30 108 3 0.04 6 0.27 0.1718 0.12
Right PL artery 29 3 0.04 6 0.25 37 2 0.02 6 0.16 0.0069 0.03
Posterior descending artery 198 7 0.10 6 0.42 327 5 0.08 6 0.39 0.0671 0.04
Data are mean 6 SD unless otherwise indicated. PL, posterolateral.
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that have examined CCTA ﬁndings of
CAD in DM and non-DM individuals,
it is nevertheless not without limitations.
Given the observational nature of the
study design, this prospective interna-
tional multicenter study is subject to
potential biases related to referral and
ascertainment. Given the latter, we chose
all-cause mortality as an end point that,
although not including other “softer” end
points such as nonfatal myocardial infarc-
tion and unstable angina, mitigates ascer-
tainment bias and allows for assessment of
an incontrovertible end point of vital clin-
ical importance (23). We performed pro-
pensity matching to identify comparator
DM and non-DM groups that were similar
in age, sex, and CAD risk factors but, in
doing so, altered the makeup of the initial
overall study group. In particular, the
prevalence of dyslipidemia and hyperten-
sionwere ostensibly higher in the non-DM
matched group compared with the initial
study population. However, our goal for
this study was to assess the excess risk of
the DM state for prevalence, extent, sever-
ity, and prognosis of CAD ﬁndings by
CCTA; for this purpose, comparator
groups require similarity and previous
methods have been well described for ap-
plication of multivariable methods ap-
plied to observational data to mitigate
confounding (24). Classiﬁcations of type
1 and 2 DM, time of onset of diabetes to
CCTA, medications, and glycemic control
were not uniformly available for patients
in our database. Longer-term follow-up of
individuals enrolled into the CONFIRM is
ongoing, and we hope to obtain this in-
formation in the future. Treatment effects
based upon CCTA CAD ﬁndings may
have precipitated salutatory therapies
that positively altered outcome. Thus,
whether percutaneous or surgical coro-
nary revascularization, enhanced medical
therapy, or lifestyle modiﬁcations altered
prognosis in this open-label multicenter
registry remains unknown. In addition,
CCTA still is a relatively novel imaging
modality that is capable of additional
measures of CAD beyond stenosis, includ-
ing atherosclerotic plaque features (e.g.,
composition, distribution) and arterial
wall remodeling (25,26). For a minority of
asymptomatic individuals with suspected
CAD, CCTA was performed for an array
of clinical indications, including preoper-
ative risk assessment, family history of
premature CAD, new-onset left ventricu-
lar systolic dysfunction, and others,
during a period early after the introduc-
tion of CCTA. Since then, appropriate use
criteria have discouraged the use of CCTA
in asymptomatic individuals, and present
study ﬁndings should thus not be taken
as a license to perform routine CCTA as-
sessment in such patients. Finally, cur-
rent-generation CT scanners are limited
by isotropic spatial resolution to 500–
750 microns. As such, partial volume ar-
tifacts may have occurred, particularly
with calciﬁed plaques (27), and these ar-
tifacts may have resulted in an overestima-
tion of stenosis severity in the current
study and a potential inability to accu-
rately assess atherosclerosis in smaller
side branches of major epicardial arteries.
The latter of these ﬁndings may be more
relevant to a DM population, who may be
more prone to diffuse patterns of athero-
sclerosis. Improvements in CT technology
Figure 1dMultivariable risk-adjusted HR for CAD extent and severity on a per-vessel basis for
matched individuals with and without DM. 1VD, one-vessel obstructive CAD .50% stenosis;
2VD, two-vessel obstructive CAD .50% stenosis; 3VD, three-vessel obstructive CAD .50%
stenosis; Nonobst, nonobstructive CAD ,50% maximal per-patient stenosis.
Table 3dUnivariable and multivariable HRs for all-cause mortality for clinical variables in matched DM and non-DM individuals
Variable
DM No DM
Univariable
HR (95% CI) P
Adjusted
HR (95% CI)* P
Univariable
HR (95% CI) P
Adjusted
HR (95% CI)* P
Age 1.05 (1.04–1.07) ,0.0001 1.07 (1.05–1.10) ,0.0001 1.12 (1.10–1.14) ,0.0001 1.11 (1.09–1.14) ,0.0001
Male sex 1.02 (0.70–1.48) 0.93 1.04 (0.65–1.66) 0.86 1.77 (1.20–2.62) 0.0039 1.09 (0.68–1.75) 0.73
Dyslipidemia 0.5 (0.34–0.73) 0.0003 0.42 (0.28–0.64) ,0.0001 0.59 (0.41–0.86) 0.0056 0.56 (0.37–0.85) 0.006
Hypertension 1.46 (0.94–2.26) 0.096 1.61 (0.96–2.67) 0.07 1.59 (1.02–2.47) 0.0413 1.94 (1.15–3.29) 0.01
Family history
of CAD 1.24 (0.84–1.83) 0.27 1.12 (0.72–1.73) 0.62 0.97 (0.66–1.44) 0.8935 1.00 (0.65–1.54) 0.99
Current smoking 1.31 (0.83–2.06) 0.25 1.35 (0.83–2.19) 0.23 1.29 (0.84–1.99) 0.2441 1.59 (1.00–2.52) 0.049
CAD pretest
likelihood
Low 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Intermediate 1.25 (0.72–2.16) 0.43 1.51 (0.77–2.96) 0.23 1.47 (0.87–2.47) 0.15 2.89 (1.61–5.21) 0.0004
High 1.39 (0.66–2.93) 0.39 1.26 (0.40–3.97) 0.7 1.13 (0.51–2.53) 0.7576 13.44 (1.57–115.2) 0.018
*Adjusted for typicality of angina and CAD pretest likelihood.
1792 DIABETES CARE, VOLUME 35, AUGUST 2012 care.diabetesjournals.org
CT angiography and patients with diabetes
(28,29) that have occurred since the initia-
tion of our study, including scanners with
higher spatial resolution that allow forCCTA
performance at lower radiation dose, may
enhance the current study ﬁndings.
In the prospective, international, mul-
ticenter CONFIRM registry of DM and
non-DM individuals similar in age, sex,
andCAD risk factors, the presence of DM is
associated with increased prevalence, ex-
tent, and severity of CAD. Assessment of
these factors confers measurable increases
in risk of all-cause mortality for DM and
non-DM individuals.
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